Tags

Type your tag names separated by a space and hit enter

Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity.
Can J Psychiatry. 2001 Jun; 46 Suppl 1:77S-90S.CJ

Abstract

BACKGROUND

The Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments partnered to produce clinical guidelines for psychiatrists for the treatment of depressive disorders.

METHODS

A standard guidelines development process was followed. Relevant literature was identified using a computerized Medline search supplemented by review of bibliographies. Operational criteria were used to rate the quality of scientific evidence, and the line of treatment recommendations included consensus clinical opinion. This section, on Axis I, Axis II, and Axis III comorbidity, is 1 of 7 articles that were drafted and reviewed by clinicians. Revised drafts underwent national and international expert peer review.

RESULTS

Comorbid depression on Axis I is particularly prevalent in patients with anxiety disorders, substance use disorders, and eating disorders, but it also occurs in patients with schizophrenia, attention-deficit hyperactivity disorder (ADHD), and dementia. Depressive comorbidity has implications for assessment, management, and outcome. The relation between depression and personality disorders is complex. Patient with this comorbidity often require longer, more intense, and multimodal therapies. Depression is also prevalent in medical illnesses, requires careful diagnosis, and responds to standard antidepressant treatments.

CONCLUSIONS

Comorbidity can influence the course and outcome of both associated conditions. Depression-specific psychotherapy and/or pharmacotherapy should be considered when comorbid depression is diagnosed.

Authors+Show Affiliations

Department of Psychiatry, University of Manitoba, Winnipeg, Manitoba.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Guideline
Journal Article
Practice Guideline
Review

Language

eng

PubMed ID

11441774

Citation

Enns, M W., et al. "Clinical Guidelines for the Treatment of Depressive Disorders. VII. Comorbidity." Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, vol. 46 Suppl 1, 2001, 77S-90S.
Enns MW, Swenson JR, McIntyre RS, et al. Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity. Can J Psychiatry. 2001;46 Suppl 1:77S-90S.
Enns, M. W., Swenson, J. R., McIntyre, R. S., Swinson, R. P., & Kennedy, S. H. (2001). Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 46 Suppl 1, 77S-90S.
Enns MW, et al. Clinical Guidelines for the Treatment of Depressive Disorders. VII. Comorbidity. Can J Psychiatry. 2001;46 Suppl 1:77S-90S. PubMed PMID: 11441774.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity. AU - Enns,M W, AU - Swenson,J R, AU - McIntyre,R S, AU - Swinson,R P, AU - Kennedy,S H, AU - ,, PY - 2001/7/10/pubmed PY - 2001/8/24/medline PY - 2001/7/10/entrez SP - 77S EP - 90S JF - Canadian journal of psychiatry. Revue canadienne de psychiatrie JO - Can J Psychiatry VL - 46 Suppl 1 N2 - BACKGROUND: The Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments partnered to produce clinical guidelines for psychiatrists for the treatment of depressive disorders. METHODS: A standard guidelines development process was followed. Relevant literature was identified using a computerized Medline search supplemented by review of bibliographies. Operational criteria were used to rate the quality of scientific evidence, and the line of treatment recommendations included consensus clinical opinion. This section, on Axis I, Axis II, and Axis III comorbidity, is 1 of 7 articles that were drafted and reviewed by clinicians. Revised drafts underwent national and international expert peer review. RESULTS: Comorbid depression on Axis I is particularly prevalent in patients with anxiety disorders, substance use disorders, and eating disorders, but it also occurs in patients with schizophrenia, attention-deficit hyperactivity disorder (ADHD), and dementia. Depressive comorbidity has implications for assessment, management, and outcome. The relation between depression and personality disorders is complex. Patient with this comorbidity often require longer, more intense, and multimodal therapies. Depression is also prevalent in medical illnesses, requires careful diagnosis, and responds to standard antidepressant treatments. CONCLUSIONS: Comorbidity can influence the course and outcome of both associated conditions. Depression-specific psychotherapy and/or pharmacotherapy should be considered when comorbid depression is diagnosed. SN - 0706-7437 UR - https://www.unboundmedicine.com/medline/citation/11441774/Clinical_guidelines_for_the_treatment_of_depressive_disorders__VII__Comorbidity_ L2 - https://medlineplus.gov/druguseandaddiction.html DB - PRIME DP - Unbound Medicine ER -